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Abstract
To be able to colonize its host, invading Salmonella enterica serovar Typhimurium must disrupt and severely affect host-
microbiome homeostasis. Here we report that S. Typhimurium induces acute infectious colitis by inhibiting peroxisome
proliferator-activated receptor gamma (PPARc) expression in intestinal epithelial cells. Interestingly, this PPARc down-
regulation by S. Typhimurium is independent of TLR-4 signaling but triggers a marked elevation of host innate immune
response genes, including that encoding the antimicrobial peptide lipocalin-2 (Lcn2). Accumulation of Lcn2 stabilizes the
metalloproteinase MMP-9 via extracellular binding, which further aggravates the colitis. Remarkably, when exposed to S.
Typhimurium, Lcn2-null mice exhibited a drastic reduction of the colitis and remained protected even at later stages of
infection. Our data suggest a mechanism in which S. Typhimurium hijacks the control of host immune response genes such
as those encoding PPARc and Lcn2 to acquire residence in a host, which by evolution has established a symbiotic relation
with its microbiome community to prevent pathogen invasion.
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Introduction
Salmonella enterica serovar Typhimurium is a Gram-negative,
facultative intracellular pathogen that causes a wide array of disorders
ranging from systemic disease to enterocolitis in multiple hosts [1]. In
mice, S. Typhimurium normally causes a disease that resembles
systemic typhoid fever. However, compromising the gut microbiome
with antibiotics prior to S. Typhimurium infection in mice has been
used to mimic salmonellosis in humans, which involves increased S.
Typhimurium colonization of the intestine coupled with a marked
host-induced inflammatory response leading to colitis [2]. Recent
reports indicate that this massive inflammatory response elicited by S.
Typhimurium is associated with increased secretion of the interleu-
kins IL-17 and IL-22 [3,4], which are critical components of mucosal
immunity to bacterial pathogens in the gut. In particular, the IL-17/
IL-22 axis mediates the recruitment of antimicrobial peptides from
the intestinal epithelial compartment, including lipocalin-2 (Lcn2) [3–
7]; these peptides dramatically affect the gut microbiota.
Lcn2 (also known as SIP24, 24p3, NGAL, uterocalin, and
siderocalin) was first co-purified and found to be covalently asso-
ciated with human neutrophil gelatinase (matrix metalloproteinase
(MMP)-9) [8,9]. This association between Lcn2 and MMP-9 has
been shown to protect MMP-9 from degradation and to preserve its
enzymatic activity [8,10]. In addition, Lcn2 functions in mamma-
lian innate immunity by chelating bacterial siderophores, thereby
sequestering iron from bacteria and inhibiting their growth [11,12].
Intriguingly, S. Typhimurium appears to be resistant to Lcn2, since
its population in the intestinal milieu expands dramatically during
inflammation [4,13,14]. This unique strategy is achieved by genes
such as those in the iroN iroBCDE gene cluster, which encodes
salmochalin, a siderophore that does not bind Lcn2 [4,13,15,16],
thus conferring a competitive advantage to S. Typhimurium over
other microbes during growth in the inflamed gut.
Recently, peroxisome proliferator-activated receptor gamma
(PPARc) has been shown to be regulated by a number of bacterial
pathogens including Helicobacter pylori and Mycobacterium tuberculosis
[17–19], greatly impacting disease severity. PPARc is a member of
the nuclear receptor superfamily of ligand-dependent transcription
factors and is predominantly expressed in adipose tissue and
colonic epithelium [20,21]. Expression has also been detected in
colonic macrophages and in T and B cells of humans and rodents
[20,22]. PPARc has been proclaimed to be a master regulator of
inflammation, a role that is achieved in part by antagonizing the
activities of the transcription factors AP-1, STAT, and NFkB
[23,24]. In vivo studies have demonstrated that PPARc ligands
actively suppress the inflammatory response by attenuating the
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production of chemokines and cytokines secreted from epithelial
cells, macrophages, and T and B lymphocytes [23–26].
The role of PPARc in the etiology and treatment of colitis has
been of great interest, because its ligands have long been used to
treat type-2 diabetes and are known to decrease the severity of colitis
induced in mouse models [27–33]. Moreover, PPARc+/2 hetero-
zygous mice exhibit increased susceptibility to experimentally
induced colitis, indicating PPARc’s involvement in maintaining
gut homeostasis [28,33]. Furthermore, the observation that
intestinal epithelium-specific ablation of PPARc aggravates dextran
sodium sulfate (DSS)-induced colitis demonstrates the strong
influence of intestine-derived PPARc on colitis severity [20]. Studies
in human subjects have revealed that colonic epithelial cells from
ulcerative colitis patients display drastically reduced expression of
PPARc, suggesting that its presence in gut epithelium may have a
protective effect against colonic inflammation in humans [29].
Despite these observations, the role of PPARc in S. Typhimurium-
induced infectious colitis remains unknown.
In this study, we explored whether S. Typhimurium regulates host
PPARc levels during infectious colitis and evaluated PPARc’s
contributions to the etiology of the disease. Our data reveal that S.
Typhimurium inhibits PPARc expression in the intestinal epithelium,
which triggers a massive innate immune response that includes
expression of Lcn2. Selective epithelial ablation of PPARc dramat-
ically increased Lcn2 expression and its secretion after S. Typhimur-
ium challenge, confirming the importance of epithelium-derived
PPARc in colitis. Furthermore, increased secretion of Lcn2 stabilized
MMP-9 via direct protein-protein interaction, which further
aggravated the colitis. Finally, we demonstrate that Lcn2-null mice
exposed to S. Typhimurium displayed significantly less-severe colitis.
Results
Regulation of PPARc in the mouse colon by
S. Typhimurium
Although PPARc signaling controls various cellular processes
during inflammation and pathogenesis, its regulation during S.
Typhimurium-induced colitis remains unexplored. To gain insight
into PPARc’s role in infectious colitis, streptomycin-pretreated
C57BL/6 mice were infected with S. Typhimurium. An incuba-
tion period of 24 h was deliberately selected to evaluate the early
phase of PPARc response, which is crucial for further downstream
effector regulation. Strikingly, S. Typhimurium infection resulted
in,60% down-regulation of PPARc gene expression in the colon,
as detected by real-time PCR (Fig. 1A). Immunoblotting revealed
a similar down-regulation of PPARc expression at the protein level
(Fig. 1B) in the colon 24 h after infection. As expected, this down-
regulation resulted in a marked reduction in the DNA-binding
activity of PPARc in colonic cells in vivo (Fig. 1C), thus reducing
PPARc’s tight control over its potential targets. A similar effect
was detected in the cecum of infected mice (Fig. S1A–C).
Since a previous study reported Toll-like receptor (TLR)-4-
dependent PPARc regulation by microbial lipopolysaccharide in
macrophages [34], we asked whether this negative regulation of
PPARc by S. Typhimurium was TLR-dependent. A significant
increase in the expression of gene encoding TLR-4, but not TLR-
2 and TLR-5, was observed in the infected mice, suggesting that
TLR4 may be involved in regulating PPARc (Fig. S2A–C).
However, S. Typhimurium infection in TLR-42/2 mice resulted
in a similar decline in PPARc expression (Fig. 1D and E),
suggesting that this PPARc regulation was independent of TLR-4.
However, the expression of TLR-2 and TLR-5 gene in the
infected TLR-42/2 mice remained unchanged, negating the
possibility of their increased activity in the absence of TLR-4 (Fig.
S2D and E). To confirm the specificity of PPARc deregulation by
S. Typhimurium, another potential gut pathogen, Citrobacter
rodentium, was used to infect mice. C. rodentium was unable to alter
host PPARc levels, confirming that the process of PPARc down-
regulation by S. Typhimurium was not a general effect (Fig. 1F).
Next, we set out to identify the cell types that predominantly
respond to S. Typhimurium. A sharp decrease in the gene
expression of PPARc occurred when cultures of colonic epithelial
cells (HT-29 cells) were infected with S. Typhimurium, suggesting
the importance of the intestinal epithelium in this process (Fig. 1G).
These observations not only indicate that S. Typhimurium
infection directly impacts PPARc levels in the colonic epithelium,
but also suggest that PPARc’s pivotal role in homeostasis within
the intestinal tract affects infectious colitis.
Specific ablation of PPARc in the intestinal epithelium
aggravates S. Typhimurium-induced colitis
To better understand the implications of this PPARc regulation
by S. Typhimurium, we bred mice harboring a floxed Pparc
(PPARcfl/fl) to mice expressing the Cre transgene under control of
the promoter of the villin gene. These mice, in which cre recom-
binase mediated the targeted disruption of PPARc in intestinal
epithelial cells, were designated PPARcVillinCre+ mice and were
used in parallel with littermate control PPARcVillinCre- or wild-
type (C57BL/6) mice. Interestingly, S. Typhimurium infection
resulted in more severe colitis in the PPARcVillinCre+ mice
compared to PPARcVillinCre- or wild-type mice at 24 h (Fig. 1H
and I). Shortening and thickening of the cecum and the colon,
which are hallmarks of colitis, were much more pronounced in
PPARcVillinCre+ mice than in wild-type or PPARcVillinCre-
mice (Fig. 1I). Of note, the S. Typhimurium-infected TLR-42/2
mice and the wild-type (C57BL/6) mice infected with C. rodentium
exhibited significantly shortened colons, indicating active colitis
(Fig. S2F and G).
S. Typhimurium cells were recovered in similar numbers from
cecum tissue and from the spleens of wild-type, PPARcVillinCre-,
and PPARcVillinCre+ mice 24 h after infection (Fig. 1J and K),
Author Summary
Enteric pathogens like S. Typhimurium convert the host
intestine into an inflamed environment in which they are
well adapted to thrive. However, the precise strategy that
this pathogen employs to achieve such favorable conditions
for its survival remains unclear. Here, we uncovered a novel
mechanism whereby S. Typhimurium inhibits the expres-
sion of the transcription factor PPARc in the host intestine,
surprisingly without TLR-4 involvement; this inhibition
worsened the severity of the host’s colitis. Subsequent
detailed analysis revealed that colitis severity was coupled
with elevated levels of antimicrobials like Lcn2, which
stabilized the pro-inflammatory endopeptidase MMP-9 in
the intestinal milieu. Combination of this escalated antimi-
crobial action together with enhanced protease activity
disrupted the intestinal homeostasis, promoting an in-
flamed environment suitable for S. Typhimurium. Interest-
ingly, using Lcn2 mutant mice we show that lack of Lcn2
effectively reduced tissue damage and the degree of
inflammation, thus supporting a pivotal role of Lcn2 and
MMP-9 in infectious colitis. Our data suggests a model
whereby the pathogenesis of S. Typhimurium involves
manipulation of the host innate immune and protease
system, here illustrated by PPARc, Lcn2 and MMP-9, to
establish colonization and infection within the host.
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Figure 1. S. Typhimurium down-regulates PPARc while inducing colitis in C57BL/6 mice. (A, B, and C) Groups of 8–10-week-old
streptomycin-pretreated C57BL/6 mice were mock- (Con) or S. Typhimurium-infected (Sal) and sacrificed after 24 h (10 mice per group). PPARc
expression in colonic scrapings was analyzed by real-time PCR (A) and by immunoblotting (B). (C) Electromobility shift assay of PPARc activity in the
nuclear extracts of colonic scrapings. (D and E) Age-matched, streptomycin-pretreated TLR42/2 mice were mock- or S. Typhimurium-infected and
sacrificed after 24 h (5 mice per group). Colonic expression of PPARc was analyzed by real-time PCR (D) or immunoblotting (E). (F) Metronidazole-
pretreated C57BL/6 mice were mock- or Citrobacter rodentium-infected, sacrificed 6 days after infection, and PPARc expression in the colon was
Role of PPARc in S. Typhimurium-Induced Colitis
PLOS Pathogens | www.plospathogens.org 3 January 2014 | Volume 10 | Issue 1 | e1003887
indicating that infection in the cecum as well as systemic
dissemination of S. Typhimurium were comparable between these
groups. Histological analysis further revealed that apart from
increased infiltration of inflammatory cells, tissue damage was
more in the colons of PPARcVillinCre+ mice compared to
PPARcVillinCre- mice and to wild-type mice after infection
(Fig. 2). Notably, similar levels of the epithelial cell markers villin 1,
cytokeratin 8, and cytokeratin 20 were detected in infected and
mock-infected colonic samples, confirming that the ratios of
epithelial cells in the colonic extracts from these groups were
consistent and did not account for the reduced levels of PPARc
(Fig. S3). These results were consistent with previous reports
indicating a protective role of PPARc in the intestinal epithelium
in experimental inflammatory bowel disease [20]. However, the
molecular mechanisms underlying these observations remain
elusive.
Depletion of epithelial PPARc in the colon triggers an
elevated immune response during infectious colitis
We previously demonstrated the direct participation of PPARc
in host-microbe crosstalk and the consequent regulation of innate
immune functions [35,36]. Moreover, PPARc has been proposed
to regulate inflammation by antagonizing the NFkB and AP-1
pathways [23,24], which in turn may modulate immune responses.
To test this hypothesis in infectious colitis, we analyzed the
activities of NFkB and AP-1 via electromobility shift assay using
nuclear extracts from colonic scrapings. As anticipated, depletion
of epithelial PPARc was coupled with a marked increase in the
activities of NFkB and AP-1 in the colon after S. Typhimurium
infection compared to littermate control (PPARcVillinCre-) mice
(Fig. 3A and B, Fig. S4).
A potential challenge was to obtain maximal numbers of
epithelial cells in colonic scrapings; epithelial cells contribute the
majority of colonic PPARc, but macrophages and B and T
lymphocytes also produce it [20,22]. To overcome this problem,
we used mucosal scrapings from the colon and tested for the
presence of PPARc transcripts through real-time PCR. Minimal
expression and activity of PPARc was detected in mock-infected
and infected PPARcVillinCre+ mice compared to littermate
control PPARcVillinCre- and wild-type (C57BL/6) mice (Fig.
S5A and B). This finding was further validated in cecum scrapings
(Fig. S1D). Thus, it was evident that epithelial cells were the major
cell type in our samples; the presence of infiltrating macrophages
and T and B cells in the colonic scrapings was possible, but
minimally contributed to PPARc production. Furthermore, no
significant differences in the expression or activity of PPARc were
detected between PPARcVillinCre- and wild-type C57BL/6 mice
(Fig. S5), justifying the use of PPARcVillinCre- mice as controls in
subsequent experiments.
We next investigated the effect of increased NFkB and AP-1
activities on key regulators of inflammation. After infection, the
expression levels of TNF-a and IL-6 in the colon were two-fold
higher in PPARcVillinCre+ mice compared to PPARcVillinCre-
mice (Fig. 3C and D). IL-6 is a key regulator of the innate T helper
type 17 (TH17) response, a critical component of mucosal
immunity to intestinal pathogens [3]. Consistent with this role,
we observed substantial increases in the expression of IL-17 and
IL-22, a typical innate TH17 response signature, in infected
PPARcVillinCre+ mice compared to infected PPARcVillinCre-
mice, as assessed via real-time PCR (Fig. 3E and F). IL-17 and IL-
22 have been linked with intestinal innate epithelial defense
mechanisms through the production of antimicrobial peptides
[3,5–7]. The expression of Lcn2, a principal target of IL-17 and
IL-22 [3,4], increased by approximately 7-fold in the colons of S.
Typhimurium-infected PPARcVillinCre- mice compared to
mock-infected mice, an increase that rose to a striking ,21-fold
change in infected PPARcVillinCre+ mice (Fig. 4A). This increase
in Lcn2 expression in infected colons was also noticeable at the
protein level (Fig. 4B and C), further confirming a hyper-
magnified Lcn2 response in infected PPARcVillinCre+ mice.
Lcn2 was similarly elevated in the cecum of these mice (Fig. S1E).
Interestingly, TLR-42/2 mice infected with S. Typhimurium also
showed a significant increase in Lcn2 expression in the colon
compared to mock-infected mice (Fig. S2H).
The expression of regenerating islet-derived 3 gamma (Reg3c),
another potent member of the host antimicrobial arsenal and a
potential target of IL-17 and IL-22 [3,37], was also tested. The
expression of Reg3c in colon followed a pattern similar to that of
Lcn2 in PPARcVillinCre- and PPARcVillinCre+ mice (Fig. 4D),
thus establishing a heightened innate immune response to S.
Typhimurium in the absence of epithelial PPARc. Moreover, S.
Typhimurium induced a significant increase in the expression and
secretion of Lcn2 (Fig. 4E and F) in parallel with PPARc down-
regulation (Fig. 1G) in colonic epithelial cells, further confirming the
importance of epithelial cells in this process. To test whether this
Lcn2 up-regulation was a cell-autonomous effect of PPARc in
epithelial cells, we next applied PPARc small interfering RNA
(siRNA) to HT-29 cells. A ,50% reduction in PPARc levels
(Fig. 4G) led to a significant increase in Lcn2 expression and
secretion in the absence of S. Typhimurium infection (Fig. 4H and
I). Moreover, when these PPARc-siRNA treated HT-29 cells were
infected with S. Typhimurium, the expression profile of Lcn2
resembled to that observed in vivo (Fig. S2I). These observations not
only confirmed the existence of a direct link between PPARc and
Lcn2, but also suggested that Lcn2 regulation by PPARcmay occur
locally in epithelial cells without the intervention of other cell types.
At this juncture, the observed dichotomy in PPARc’s role in
infectious colitis was surprising. Although we initially observed that
the absence of PPARc led to increased colitis severity (Fig. 1H and
I; Fig. 2), in sharp contrast we also detected a simultaneous
elevated innate immune response that seemed to serve a protective
role. Taken together, these results reflect PPARc’s tight control
over intestinal homeostasis in the host during S. Typhimurium
pathogenesis. We next questioned the rationale behind this
heightened Lcn2 expression, given that S. Typhimurium is
typically resistant to Lcn2’s antimicrobial activity [4,13,15,16],
and speculated that Lcn2 may have a more diverse role in the
disease process.
Lcn2 promotes MMP-9 stability and contributes to colitis
severity
Having established that Lcn2 expression was markedly
increased in PPARcVillinCre+ mice (Fig. 4A–C), we next sought
to dissect its possible role in the increased colonic damage
analyzed by real-time PCR. (G) HT-29 cells were mock- or S. Typhimurium-infected for 6 h, incubated for another 18 h without the pathogen, and
PPARc expression was analyzed by real-time PCR. (H) Macroscopic image of whole cecum after mock or S. Typhimurium infection in C57BL/6 (WT),
PPARcVillinCre2 (Cre2), or PPARcVillinCre+ (Cre+) mice. (I) Quantitation of colon lengths in the respective mouse groups. Recovery of S.
Typhimurium from cecum tissue (J) and spleen (K) 24 h after infection. Error bars depict 6 standard error of the mean. *p,0.001, **p,0.05. CFU,
colony-forming units; NS, not significant.
doi:10.1371/journal.ppat.1003887.g001
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observed in PPARcVillinCre+ mice in the absence of PPARc
(Fig. 2), suggesting ongoing exaggerated protease action. Interest-
ingly, Lcn2 has been shown to increase the stability of MMP-9 by
protecting it from degradation, resulting in an increase in its
enzymatic activity independent of transcriptional regulation
[8,10,38,39]. To test this hypothesis, we analyzed the activity of
gelatin agarose-purified secreted gelatinases by zymography using
phosphate-buffered saline (PBS) extracts of colonic scrapings of
mock- or S. Typhimurium-infected mice. Interestingly, we
detected a ,140 KDa band representative of Lcn2-bound
proMMP-9 (proMMP-9/Lcn2) in S. Typhimurium-infected
PPARcVillinCre- mice that peaked to an ,6-fold increase in
Figure 2. Colitis severity is more pronounced in PPARcVillinCre+ mice than in wild-type mice. Sections of colon from mock- or S.
Typhimurium-infected wild-type (C57BL/6) and PPARcVillinCre+ mice were stained with hematoxylin and eosin (6 mice per group). (A and B) Wild-
type mice mock-infected. (C and D) Wild-type mice infected with S. Typhimurium. PPARcVillinCre2 mice mock-infected (E and F), or infected with S.
Typhimurium (G and H). PPARcVillinCre+ mice mock-infected (I and J), or infected with S. Typhimurium (K and L). All scale bars are 100 mm. Pathology
scoring was performed for neutrophil infiltration (M). (N) Myeloperoxidase (MPO) activity in colonic extracts of mice, measured per mg of total
protein. In panels M and N, mock (Con)- or S. Typhimurium (Sal)-infected PPARcVillinCre+ (Cre+) or littermate control PPARcVillinCre2 (Cre2) mice
were examined. Error bars =6standard error of the mean. **p,0.01.
doi:10.1371/journal.ppat.1003887.g002
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infected PPARcVillinCre+ mice (Fig. 5A and B). Surprisingly, this
increase in the proMMP-9/Lcn2 band in PPARcVillinCre+ mice
was associated with a massive increase in the activity of proMMP-
9 (detected by zymography Fig. 5A), indicating an increased
stability of proMMP-9. The activity of proMMP-9 increased by
,6 fold in PPARcVillinCre- mice and ,15 fold in PPARcVil-
linCre+ mice after infection, while MMP-9 activity rose from ,4
fold in PPARcVillinCre- mice to ,7 fold in PPARcVillinCre+
mice after infection (Fig. 5A and B). In contrast, MMP-2 activity
remained almost unchanged between groups. Importantly, no
significant difference in MMP-9 gene expression occurred between
the PPARcVillinCre- and PPARcVillinCre+ infected groups, as
detected by real-time PCR (Fig. 5C), which confirmed that the
differences in MMP-9 activity were independent of transcriptional
regulation. Furthermore, MMP-2 expression was similar between
the infected and mock-infected groups (Fig. 5D). No noticeable
difference in the expression of TIMP-1, the endogenous inhibitor
of MMP-9, was observed between the infected mice groups
(Fig. 5E), eliminating the possibility of its involvement in the
observed deregulation of MMP-9 activity.
To further confirm this phenomenon, we next analyzed the
protein levels of MMP-9 and Lcn2 by immunoblotting gelatin-
agarose-purified PBS extracts of colonic scrapings under non-
reducing conditions. As anticipated, the ,140 KDa proMMP-9/
Lcn2 band, the level of which increased by ,5 fold in infected
PPARcVillinCre- mice, peaked at ,15-fold in PPARcVillinCre+
Figure 3. PPARc depletion from intestinal epithelium augments the immune response to S. Typhimurium infection. (A and B) Nuclear
extracts from colonic scrapings of mock (Con)- or S. Typhimurium (Sal)-infected PPARcVillinCre+ (Cre+) or littermate control PPARcVillinCre2 (Cre2)
mice were assessed for NFkB (A) and AP-1 (B) activities by electromobility shift assay (6–8 mice per group). The expression levels of TNF-a (C), IL-6 (D),
IL-17 (E), and IL-22 (F) in the colons of mock- or S. Typhimurium-infected PPARcVillinCre+ or PPARcVillinCre2 mice were measured by real-time PCR.
Error bars =6 standard error of the mean. *p,0.001, **p,0.01.
doi:10.1371/journal.ppat.1003887.g003
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infected mice (Fig. 5F and G). This increase led to an ,15-fold
increase in proMMP-9 protein levels in PPARcVillinCre- infected
mice and reached a striking increase of ,40 fold in PPARcVil-
linCre+ infected mice, while MMP-9 climbed ,5 fold in
PPARcVillinCre+ infected mice (Fig. 5F and G). When the gels
were re-probed for Lcn2, bands at exactly the same location as the
,140 KDa band, characteristic of proMMP-9 bound to Lcn2,
were detected (Fig. 5F and G). These results indicate that Lcn2 is
secreted from the intestinal epithelium, in accordance with
previous reports [3], and more importantly confirm the binding
of Lcn2 to secreted proMMP-9 in the intestinal milieu, which is
pivotal for subsequent pathological processes. However, since the
increase in the levels of the Lcn2/MMP-9 complex in the
intestinal milieu correlates with the increased infiltration of
neutrophils it is possible that these cells may contribute to the
observed elevation of Lcn2/MMP-9. It is noteworthy that the ,6-
fold increase in Lcn2 secretion in S. Typhimurium-infected
PPARcVillinCre+ mice (Fig. 5F and G) did not precisely
correspond to its ,15-fold increase at the expression level
(Fig. 4A–C), because it represented only the Lcn2 fraction bound
to proMMP-9 during gelatin-agarose purification of secreted
gelatinases. Reasonably, no low molecular-weight band for Lcn2
alone was detected (Fig. 5F). It may also be noted that the
proportion of bound or free Lcn2 or proMMP-9 at any given point
would largely depend on the availability, stability, and importantly
the stoichiometry of binding between these molecules. Taken
together, these results conclusively indicate that lack of epithelial
PPARc substantially elevates Lcn2 expression and its secretion in
the intestinal milieu during S. Typhimurium infection, resulting in
increased MMP-9 stabilization and activity.
Absence of Lcn2 significantly protects mice from S.
Typhimurium-induced colitis
To validate the observed involvement of Lcn2 in S. Typhimur-
ium-induced colitis, we next checked for colitis induction in
streptomycin-pretreated Lcn22/2 mice mock- or S. Typhimur-
ium-infected for 24 h. As expected from the above observations,
marked reductions in the extent and severity of S. Typhimurium-
induced colitis were observed in mice devoid of Lcn2 (Fig. 6A and
B). Shortening and thickening of the cecum and colon were
considerably restricted in the Lcn22/2 mice 24 h after S.
Typhimurium challenge (Fig. 6A and B). These results were
confirmed by observations of reduced thickening of the mucosa
and sub-mucosa, with negligible tissue damage (Fig. 6C–H).
However, a modest increase in infiltrating cells and consequent
myeloperoxidase (MPO) activity was noted (Fig. 6G and H).
Moreover, the number of S. Typhimurium in the cecum and
spleen of these Lcn22/2 mice was comparable to that of wild-type
mice after 24 h (Fig. 6I and J). As expected, Lcn2 expression was
not detected in these mice by real-time PCR (Fig. S6A) or by
immunoblotting (Fig. S6B) of the colons of Lcn22/2 mice. Thus,
these observations highlight Lcn2’s unique role in the induction
and severity of infectious colitis.
To more precisely track the molecular mechanisms active in
Lcn22/2 mice after S. Typhimurium infection, we assessed the
secretion of gelatinases in the colon. We observed an ,3.5-fold
increase in proMMP-9 activity in Lcn22/2 mice after infection
versus mock infection (Fig. 7A and B), compared to a ,6-fold
increase in PPARcVillinCre- infected mice (Fig. 5A and B). No
notable differences in the activities of MMP-9 and MMP-2 were
detected between groups. The basal secretion of gelatinases was
similar in PPARcVillinCre- and Lcn22/2 mock-infected mice
(Fig. S7A), justifying the comparison between these groups in this
case.
We next examined the levels of secreted MMP-9 using gelatin-
purified colonic extracts of mock- or S. Typhimurium-infected
Lcn22/2 mice. Compared to the ,15-fold increase in secreted
proMMP-9 that was observed in PPARcVillinCre- mice after
infection (Fig. 5F and G), a mere ,3-fold increase in the levels of
secreted proMMP-9 was detected in Lcn22/2 mice after infection,
suggesting reduced extracellular stability and possible degradation
of MMP-9 protein in the absence of Lcn2 (Fig. 7C and D). No
significant difference in the colonic expression of MMP-9 was
detected between Lcn22/2 and Lcn2+/+ mice after infection
(Fig. 7E), confirming that the differences in the protein levels of
MMP-9 were due to impaired stability. Moreover, colonic
expression of MMP-2 and TIMP-1 was similar in Lcn2+/+ and
Lcn22/2 mice after infection (Fig. S7B and C), excluding their
involvement in this process.
To investigate any possible mechanistic differences between the
Lcn22/2 and Lcn2+/+ mice during S. Typhimurium infection, we
validated several key regulators involved in the pathophysiology of
infectious colitis. Real-time PCR revealed no appreciable differ-
ences in the down-regulation of PPARc by S. Typhimurium
between Lcn22/2 and Lcn2+/+ mice (Fig. S8A), confirming that
PPARc regulation by S. Typhimurium was essentially the same in
Lcn22/2 mice. Consequently, the expression levels of TNF-a and
IL-6 were similar between the infected groups (Fig. S8B and C).
Colonic expression of IL-17 and IL-22 also exhibited negligible
differences between Lcn22/2 and Lcn2+/+ infected mice (Fig. S8D
and E), as did Reg3c expression (Fig. S8F). Together, these
observations suggest that the mechanistic chain of events during S.
Typhimurium infection in wild-type and Lcn22/2 mice was
fundamentally similar; the absence of Lcn2 exclusively conferred
protection to these mice against S. Typhimurium-induced colitis.
To determine whether the regulation of PPARcby S. Typhi-
murium is a transient effect or whether the Lcn22/2 mice are
protected at later stages of infection, we infected PPARcVillinCre-
, PPARcVillinCre+, Lcn22/2, and Lcn2+/+ mice with S.
Typhimurium and sacrificed them after 72 h. Long-term S.
Typhimurium infection resulted in more severe colitis in
PPARcVillinCre+ mice compared to PPARcVillinCre- mice,
while Lcn22/2 mice were significantly protected against colitis
(Fig. S9A); colonic shortening displayed a similar profile (Fig. S9B).
There was no significant difference in the number of S.
Typhimurium recovered from the cecum or spleen of these mice
72 h after infection (Fig. S9C and D). Histological analysis
Figure 4. Colonic Lcn2 expression in PPARcVillinCre+mice increases after S. Typhimurium challenge. (A and B) Expression levels of Lcn2
in the colons of mock (Con)- or S. Typhimurium (SaI)-infected PPARcVillinCre+ (Cre+) or PPARcVillinCre2 (Cre2) mice (6–8 mice per group) were
measured by real-time PCR (A) and by immunoblotting (B). (C) Quantitation of changes in protein expression from the immunoblot in panel B and
from another representative blot from independent experiments. (D) Expression levels of Reg3c in the colons of mock- or S. Typhimurium-infected
mice were measured by real-time PCR. (E and F) HT-29 cells were mock- or S. Typhimurium-infected for 6 h, incubated for another 18 h without the
pathogen, and Lcn2 expression (E) and secretion (F) were analyzed by real-time PCR and immunoblotting, respectively. (G–I) HT-29 cells were treated
with siRNA directed against PPARc, and the expression of PPARc (G) and Lcn2 (H) in uninfected cells was analyzed by real-time PCR. The secretion of
Lcn2 was analyzed by immunoblotting using concentrated culture supernatant (I). Error bars =6 standard error of the mean. *p,0.005, **p,0.01.
doi:10.1371/journal.ppat.1003887.g004
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revealed more severe colitis in PPARcVillinCre+ mice than in
PPARcVillinCre- mice, with significantly increased neutrophil
infiltration and MPO activity (Fig. S9E-L and S9U-W). Although
the Lcn22/2 mice exhibited moderate colitis, they were associated
with marked reductions in neutrophil infiltration, edema, and
MPO activity compared to the rest of the groups 72 h after
infection (Fig. S9M–W). Interestingly, PPARc expression was still
significantly reduced after 72 h in the colons of PPARcVillinCre-
mice, confirming that PPARc regulation by S. Typhimurium was
not a transient event (Fig. S9X and Y).
Discussion
Intestinal pathogens employ diverse strategies to modulate the
host environment in order to survive in this competitive niche. The
approaches that individual pathogens adopt depend largely on the
tenure of their residence in the host. For instance, H. pylori up-
regulates host PPARc as part of a feedback mechanism to suppress
exaggerated inflammation, ensuring its unperturbed long-term
survival in the host [17,19]. Similarly, M. tuberculosis induces
PPARc expression in infected individuals and subsequently
interacts with host PPARc by modulating macrophage function
for its survival [18]. Here, we unravel a novel mechanism used by
S. Typhimurium to down-regulate PPARc in the intestinal
epithelium, initiating acute inflammation via the host immune
and protease machinery, thereby transforming the intestine into a
more hostile niche where it is best adapted to survive and outgrow
its competitors. This TLR-4-independent regulation of PPARc by
S. Typhimurium seems to be characteristic of this pathogen, since
C. rodentium infection, did not alter PPARc levels.
PPARc activation has been shown to ameliorate the severity of
inflammatory bowel disease in rodent DSS, trinitrobenzene
sulphonic acid, and ischemic colitis models [20,27,30,32,33].
Since PPARc is expressed in epithelial cells as well as in immune
cells infiltrating colonic tissue during inflammation, the cell type
that mainly contributes to PPARc production during colitis
remains a point of contention. Interestingly, clinical reports
indicate that PPARc expression in colonic epithelium is impaired
in ulcerative colitis patients, while its expression in inflammatory
cells remains normal [40]. This observation was corroborated
by Adachi et al., who reported that PPARc expressed in the
colonic epithelium has an endogenous role in protection against
DSS-induced colitis [20]. These findings, together with our data in
Fig. 1G, demonstrating PPARc regulation by S. Typhimurium in
human colonic epithelial cells, prompted us to use epithelial-
specific PPARc-null mice to unravel the chain of events that occur
during S. Typhimurium-induced colitis. This strategy allowed us to
magnify the subtle molecular changes induced by S. Typhimurium
in the host via down-regulation of epithelial PPARc. S.
Typhimurium induced much more severe colitis in these mice
(Fig. 1H and I; Fig. 2), highlighting, for the first time, the
importance of intestinal epithelium-derived PPARc in protection
against bacterial pathogenesis.
Our data demonstrate that S. Typhimurium-induced depletion
of epithelial PPARc uncouples PPARc’s tight control over the
inflammatory transcription factors NFkB and AP-1, resulting in
the release of the pro-inflammatory cytokines TNF-a and IL-6.
This influx of pro-inflammatory cytokines from the intestinal
epithelium initiates an acute-phase immune response character-
ized by elevated expression of IL-17 and IL-22. These results are
consistent with a recent report by Geddes et al. of the induction of
the innate TH17 response by S. Typhimurium during the early
phases of infection [3]. Collectively, our results imply that these
inflammatory signaling circuits are orchestrated by S. Typhimur-
ium during the early phases of infection via the regulation of
epithelial PPARc, which is pivotal for the entire process.
The secretion of IL-17 and IL-22 in the inflamed colon, which is
initiated by S. Typhimurium, has been shown to facilitate the
production of antimicrobials, including Lcn2, from the intestinal
epithelium [3–7]. Our observations confirm the contribution of
IL-17 and IL-22 to Lcn2 production and secretion, but also
suggest that S. Typhimurium-induced increases in NFkB and AP-1
activity in epithelial cells via PPARc down-regulation may directly
influence Lcn2 expression in the same cells independent of IL-17
and IL-22 (Fig. 7F). This hypothesis was further corroborated by
the induction of Lcn2 in non-infected human colonic epithelial
cells treated with siRNA directed against PPARc. It seems
reasonable to assume that S. Typhimurium may utilize this more
direct pathway of Lcn2 regulation, since Lcn2 expression is known
to be regulated by NFkB or even AP-1 [41,42]; importantly, this
entire sequence of events may occur in affected epithelial cells.
Understanding the rationale behind the substantial increase in
Lcn2 secretion from the intestinal epithelium during S. Typhimur-
ium infection, which typically utilizes salmochalin, a siderophore
resistant to Lcn2 action [4,13,15,16], for iron uptake, was perhaps
the biggest challenge in this study. Here, we documented that S.
Typhimurium-induced elevated influx of secreted Lcn2 in the
intestinal milieu leads to stabilization and a significant increase in
MMP-9 activity, through direct extracellular protein-protein
binding (Fig. 7F). MMP-9, a member of a family of zinc-
dependent endopeptidases that have broad substrate specificity,
has been shown to play a pivotal role in the degradation and
remodeling of the extracellular matrix during bacterial pathogen-
esis [19,43]. Moreover, MMP-9-null mice exposed to DSS or to S.
Typhimurium were previously significantly protected from colitis
[44,45], confirming MMP-9’s importance in the etiology of the
disease. Although MMPs are secreted by a variety of cell types, such
as fibroblasts, epithelial cells, endothelial cells, neutrophils, macro-
phages, and lymphocytes, MMP-9 is predominantly expressed in
epithelial cells and in inflammatory cells during colitis [44,46]. Our
data suggest that this crosstalk between Lcn2 and MMP-9 in the
inflamed gut, which results in increasedMMP-9 activity, was crucial
for the deleterious impact on the intestinal mucosa observed during
infectious colitis. This novel mechanism by which S. Typhimurium
exploits the host Lcn2 and MMP-9 synergy to aggravate
inflammation and colitis severity is critical, as it calls for the
Figure 5. Elevated levels of Lcn2 in the colonic milieu of S. Typhimurium-infected mice stabilize proMMP-9. (A) The activities of MMP-9
and MMP-2 in gelatin-agarose-purified PBS (secreted) extracts of mock (Con)- or S. Typhimurium (SaI)-infected PPARcVillinCre+ (Cre+) or
PPARcVillinCre2 (Cre2) mouse colonic tissues were analyzed by gelatin zymography (6–8 mice per group). (B) Quantitation of gelatinolytic activities
from the zymogram in panel A and from two other representative zymograms from independent experiments. Expression levels of MMP-9 (C), MMP-2
(D), and TIMP-1 (E) in the colons of the respective groups were measured by real-time PCR. (F) Protein levels of MMP-9 and Lcn2 in the colons of the
respective mouse groups were assessed by immunoblotting using purified PBS extracts under non-reducing conditions. Flow-through from gelatin-
agarose purification was probed for b-actin as a loading control. (G) Quantitation of changes in protein levels from the immunoblot in panel F and
from another representative blot from independent experiments. Error bars =6 standard error of the mean. *p,0.001 vs. PPARcVillinCre- mice
infected with S. Typhimurium. NS, not significant.
doi:10.1371/journal.ppat.1003887.g005
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reinterpretation of studies on microbial pathogenesis; other
potential pathogens may also employ similar mechanisms.
Interestingly, mice lacking Lcn2 were considerably protected
against S. Typhimurium-induced colitis even at the later stages of
infection, confirming the key role of this secreted protein in S.
Typhimurium pathogenesis. We detected no significant differences
in the overall mechanism acting in Lcn2-null and wild-type
infected mice, with the exception of a decrease in MMP-9 stability
and activity in the colon. Our observations of Lcn2-null mice
exposed to S. Typhimurium, which indicated increased expression
of IL-17, IL22, and TNF-a, are consistent with the findings of
Raffatellu et al. [4]. We also noted moderate inflammation in the
colon during the later stages of infection. However, disease severity
may be impacted by differences in experimental setup, including S.
Typhimurium strains, bacterial load and phase of growth in the
inoculum, and importantly, differences in intestinal microflora
between mice.
In conclusion, our investigation unveiled a novel pathogenic
mechanism utilized by S. Typhimurium to thrive and to induce
colitis in its host. This study motivates the development of
therapeutic interventions directed against this Lcn2-dependent,
MMP-9-driven tissue degradation pathway to combat salmonel-
losis. However, research aimed toward a better understanding of
the pathogenic mechanisms of S. Typhimurium or other
pathogens in the gut remains an exciting area for future studies.
Materials and Methods
Ethics statement
All protocols involving animals were approved by the Regional
Animal Research Ethical Board, Stockholm, Sweden, following
proceedings described in European Union legislation (Council
Directive 86/609/EEC). Animal husbandry was in accordance
with institutional guidelines at Karolinska Institutet and was
approved by the above-mentioned ethical board (Stockholms
norra djurfo¨rso¨ksetiska na¨mnd, Ref: N 100/10).
Bacterial strains, culture and colonization assessment
The naturally streptomycin-resistant wild type strain S.
enterica serovar Typhimurium SL1344 [47], a generous gift
from Prof. Mikael Rhen was used in this study. Naturally
occurring naldixic acid-resistant Citrobacter rodentium, DBS100
(ATCC 51459) was also used for mouse infection. Prior to
inoculation into host mice, strain SL1344 and C. rodentium were
grown overnight at 37uC in Luria-Bertani (LB) broth, diluted
1:20 in fresh medium, and sub-cultured for 3–4 h under mild
aeration until an optical density of 0.4 to 0.6 at 600 nm was
reached. Bacteria were washed twice in cold PBS and then
suspended in cold PBS for mouse inoculation.
The cecum and spleen from post-sacrifice mice were collected in
1 mL of sterile PBS. Samples were kept on ice, minced, and
homogenized. Serial dilutions of the homogenates were plated on
LB agar plates supplemented with 100 mg/mL streptomycin to
enumerate S. Typhimurium. Plates were incubated overnight at
37uC, and colonies were counted thereafter.
Cell-culture assays
The human epithelial cell line HT-29 (ATCC-HTB-38) was
obtained from the American Type Culture Collection. Cells were
grown in RPMI 1640 (Invitrogen) medium supplemented with
10% heat-inactivated fetal calf serum (Invitrogen). Cells were
maintained in a 37uC humidified atmosphere with 5% CO2.
Epithelial morphogenesis was monitored via microscopy; cell
densities for each experiment did not exceed 80% to prevent
contact inhibition.
For co-culture experiments, cells were treated with S. Typhi-
murium (0.256107 cells/well; 10:1 bacterial cells:eukaryotic cells)
for 6 h. Controls were treated with culture medium only. After 6 h
medium was removed, cells were washed, fresh medium with 1%
penicillin/streptomycin was added, and the cells were incubated
for 18 h, after which the cells were collected and lysed.
For siRNA experiments HT-29 cells were plated at a density of
0.06256105 cells/cm2. Down-regulation of PPARc transcripts was
achieved with SMART Pool siRNA directed against PPARc
(Thermo Scientific). Controls were transfected with non-targeting
siRNA (Thermo Scientific) at a final siRNA concentration of
40 nM. Transfection was carried out according to the manufac-
turer’s protocol using DharmaFECT 4 (Thermo Scientific) reagent
at a final concentration of 0.3%.
Bacterial infection in mice
Specific pathogen-free C57BL/6 wild-type mice carrying a
targeted disruption of the gene encoding PPARc in intestinal
epithelial cells were generated by breeding animals harboring a
floxed Pparc (PPARcfl/fl) [48] to mice expressing the Cre transgene
under control of the villin promoter; these mice were designated as
PPARcVillinCre+, and their littermate control mice were
designated as PPARcVillinCre2. Lcn2-deficient (Lcn22/2) mice
[11,38] and TLR42/2 mice (Jackson Laboratory Stock No:
007227) aged 8–10 weeks were also used in this study. The
Lcn22/2 mice were generated previously [11] and were back-
crossed into the C57BL/6 background for at least 10 generations
[38]. All experiments were performed under standard controlled
conditions and all efforts were made to minimize animal suffering.
Groups of mice were pretreated with streptomycin (0.1 mL of a
200 mg/mL solution in sterile water) orally 24 h prior to either
mock (PBS) or S. Typhimurium (16108 colony-forming units/
mouse) inoculation via gavage. At 24 h or 72 h after infection,
mice were euthanized and the cecum, spleen, and colon were
collected for analysis. For C. rodentium infection, mice were given
metronidazole at 750 mg/L for 4 days, which was withdrawn
prior to inoculation with 16109 colony-forming units/mouse via
gavage. C. rodentium-infected mice were sacrificed 6 days after
infection [49]. Colon lengths were measured using a centimeter scale.
Tissue extraction, partial purification of gelatinases, and
zymography
The mucosal layer of the colon was carefully scraped and
suspended in PBS containing protease inhibitors (Roche), minced,
and centrifuged at 6000 g for 15 min. The supernatant was collected
for use as PBS extracts for the analysis of secreted proteins, while the
Figure 6. Lcn22/2 mice are markedly protected from S. Typhimurium-induced colitis. (A and B) Groups of 8–10-week-old, streptomycin-
pretreated Lcn22/2 mice were mock (Con)- or S. Typhimurium (Sal)-infected and sacrificed after 24 h (10 mice per group). (A) Macroscopic image of
whole cecum 24 h after infection. (B) Quantitation of colon lengths in mock- or S. Typhimurium-infected Lcn22/2 mice. (C–F) Sections of colon from
mock- or S. Typhimurium-infected Lcn22/2 mice were stained with hematoxylin and eosin (scale bars, 100 mm). Lcn22/2 mice mock-infected (C and
D), or infected with S. Typhimurium (E and F). Pathology scoring was performed for neutrophil infiltration (G). (H) Myeloperoxidase (MPO) activity was
determined in the colonic extracts of mice, as measured per mg of total protein. Recovery of S. Typhimurium from cecum tissue (I) and spleen (J),
24 h after infection. Error bars =6 standard error of the mean. **p,0.05. NS, not significant.
doi:10.1371/journal.ppat.1003887.g006
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Figure 7. Mechanism of S. Typhimurium-induced intestinal damage during colitis. (A) Secretion of MMP-9 and MMP-2 in the colons of
mock (Con)- or S. Typhimurium (SaI)-infected Lcn22/2 mice was analyzed by gelatin zymography using gelatin-agarose-purified PBS extracts (6–8
mice per group). (B) Quantitation of gelatinolytic activities from the zymogram in panel A and from another representative zymogram from
independent experiments. (C) MMP-9 protein levels in the colons of mice from the respective groups were assessed by immunoblotting purified PBS
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pellet was re-extracted in lysis buffer (10 mM Tris-HCl [pH 8],
150 mMNaCl, 1% Triton X-100, and protease inhibitors) to obtain
Triton X-100 extracts [41]. For partial purification of MMP-9 and
MMP-2, PBS extracts of the respective samples were incubated with
gelatin-agarose beads (Sigma) at 4uC for 1 h followed by centrifu-
gation at 1500 rpm. The supernatant was collected as flow-through
and used as a loading control. The pellet was washed twice with PBS
through centrifugation at 1500 rpm and the gelatinases were eluted
in Lammeli sample loading buffer. For assays of MMP-9 andMMP-
2 activity, gelatin zymography was performed as described
previously [43]. Zymographic bands were quantified using Lab-
Image software (KAPELAN).
Immunoblotting
Triton X-100 extracts (50 mg/lane) from colon samples were
immunoblotted. Gelatin-agarose-purified PBS extracts were im-
munoblotted under non-reducing conditions. Cell-culture super-
natants were concentrated using a vacuum centrifuge and
volumetrically analyzed by immunoblotting.
Immunoblots were probed with anti-PPARc (Cell Signaling),
anti-MMP-9 (Abcam), anti-Lcn2 (Abcam), and anti-b-actin (Santa
Cruz Biotechnology) antibodies. Immunodetection with an appro-
priate secondary peroxidase-conjugated antibody (DAKO) was
followed by electrochemiluminescence (Santa Cruz Biotechnology).
Quantification of protein bands was performed with the LabImage
software. Fold changes were calculated using densitometry values
for bands representing proteins of interest, normalized to densi-
tometry values for b-actin bands of respective samples. Represen-
tative blots from at least two independent experiments are shown.
Real-time PCR
Total RNA was extracted with an RNeasy Mini Kit (Qiagen),
and cDNA was synthesized with SuperScript II (Invitrogen), both
procedures according to the manufacturers’ protocols. We
measured gene expressions with SYBR Green (Applied Biosys-
tems)-based quantitative reverse transcription PCR. Primers were
designed and tested according to Applied Biosystems recommen-
dations (Table S1). Sample setups always included at least five
biological replicates and experimental triplicates. The changes in
mRNA expression of respective samples compared to control were
expressed as DDCt=DCtcontrol2DCtrespective samples (DCt=Ct
value for the gene of interest - Ct value for b-actin of the
respective sample). Relative expressions in the genes in respective
samples were calculated as 2DDCt [19].
Electromobility shift assay
Nuclear extracts from colonic scrapings were prepared accord-
ing the nuclear extraction protocol of Schreiber [50]. DNA
binding was assayed with 10 mg of nuclear extract in binding
buffer (25 mM HEPES [pH 7.9], 70 mM KCl, 10% glycerol,
5 mM dithiothreitol, and 1 mg polydIdC (Amersham)) in the
presence of 50,000 cpm of a radiolabeled oligonucleotide probe.
The probe for PPARc (sequences 59-TCTCTCTGGGTGAAA-
TGTGC-39 and 59-AGAGGCACATTTCACCCAGAGAGA-39)
has high PPARc-specificity and moderate affinity to ensure weak
binding to other PPARs [35]. Probes for NFkB (sequences 59-
GATCCAGAGGGGACTTTCCGAG-39 and 59- TCGACTCG-
GAAAGTCCCCTCTG-39) and for AP-1 (sequences 59-CTGAT-
GACTCAGAG-39 and 59-CTCTGAGTCATCAG-39) were used.
polydIdC and probe were added to extracts and incubated for 30 min
before gel electrophoresis. Bands were quantified with LabImage.
Histology and pathology scoring
The colons of mock- or S. Typhimurium-infected mice from the
respective groups were sectioned for histological studies. Distal
part of the colon was used for histological analysis in all cases.
Tissue samples were fixed in 10% formalin and embedded in
paraffin. Sections (5 mm) were cut with a microtome, stained with
hematoxylin and eosin [43], and observed under a Zeiss
microscope. Images were captured using Axiovision, LE 64
software (Carl Zeiss Microscopy) at original magnification 5610
and 20610 and processed in Adobe Photoshop CS6 (Adobe
Systems incorporated). Pathology scoring for neutrophil infiltra-
tion and edema was rated from 0 to 5 according to severity, under
blinded conditions, by an experienced pathologist (RMB).
MPO activity assay
Whole-cell extracts from colonic scrapings were assayed for
MPO activity using the Myeloperoxidase Activity Assay Kit
(Invitrogen) following the manufacturer’s protocol.
Statistical analysis
Densitometry data were fitted using SigmaPlot 2001 (SPSS) or
GraphPad Prism 5 (GraphPad Software). Data are presented as
the mean 6 standard error of the mean. Between-group
comparisons were carried out using either Student’s t-test or
Student-Newman-Keuls test (ANOVA).
Supporting Information
Figure S1 S. Typhimurium down-regulates PPARc in
the cecum during colitis. (A, B, and C) Groups of 8–10-week-
old, streptomycin-pretreated C57BL/6 mice (WT) were mock
(Con)- or S. Typhimurium (SaI)-infected and sacrificed after 24 h
(10 mice per group). PPARc expression in the cecum was analyzed
by real-time PCR (A) and by immunoblotting (B). (C) Electromobility
shift assay of PPARc activity in nuclear extracts from the cecum. (D
and E) Groups of age-matched, streptomycin-pretreated PPARc-
VillinCre+ (Cre+) or littermate control PPARcVillinCre2 (Cre2)
mice were mock- or S. Typhimurium-infected and sacrificed after
24 h (6–8 mice per group). PPARc (D) and Lcn2 (E) expression in the
cecum was analyzed by real-time PCR. Error bars=6 standard
error of the mean. *p,0.005, **p,0.05.
(TIF)
Figure S2 S. Typhimurium down-regulates PPARc in-
dependent of TLR-4 signaling. (A, B, and C) Groups of 8–10-
week-old, streptomycin-pretreated C57BL/6 mice were mock
(Con)- or S. Typhimurium (SaI)-infected and sacrificed after 24 h
extracts under non-reducing conditions. Flow-through from the purification was used as a loading control. (D) Quantitation of changes in protein
levels from the immunoblot in panel C and from another representative blot from independent experiments. (E) MMP-9 expression levels in the
colons of mock- or S. Typhimurium-infected Lcn2+/+ and Lcn22/2 mice were measured by real-time PCR. Error bars =6 standard error of the mean.
*p,0.0001 vs. Lcn22/2 control. NS, not significant. (F) S. Typhimurium down-regulates PPARc in intestinal epithelial cells. The subsequent decrease in
PPARc activity leads to the activation of NFkB and AP-1 and the release of TNF-a and IL-6. Through activation of the acute-phase immune response,
TNF-a and IL-6 induce IL-17 and IL-22. NFkB and AP-1 activation either directly or in conjunction with IL-17 and IL-22 induce Lcn2 expression in
epithelial cells and its consequent secretion into the intestinal milieu. Extracellular binding of Lcn2 to secreted MMP-9 increases MMP-9 stabilization
and activity, resulting in extensive tissue damage during infectious colitis.
doi:10.1371/journal.ppat.1003887.g007
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(10 mice per group). The expression of TLR-4 (A), TLR-2 (B), and
TLR-5 (C) in the colon was analyzed by real-time PCR. (D–F and
H) Age-matched, streptomycin-pretreated TLR42/2 mice were
mock- or S. Typhimurium-infected and sacrificed after 24 h (5 mice
per group). Expression of TLR-4 (D), TLR-2 (E), and Lcn2 (H) in
the colon was analyzed by real-time PCR. (F) Quantitation of colon
lengths in the respective mouse groups. (G) Metronidazole-
pretreated C57BL/6 mice were mock- or C. rodentium-infected,
sacrificed 6 days after infection and colon lengths in the respective
mice were quantified. (I) HT-29 cells were treated with siRNA
directed against PPARc, infected with S. Typhimurium and the
expression of Lcn2 in infected cells was analyzed by real-time PCR.
Error bars =6 standard error of the mean. *p,0.005.
(TIF)
Figure S3 Analysis of epithelial cell markers in colonic
scrapings. Groups of age-matched, streptomycin-pretreated
PPARcVillinCre+ (Cre+) or littermate control PPARcVillinCre2
(Cre2) mice were mock (Con)- or S. Typhimurium (SaI)-infected
and sacrificed after 24 h (6–8 mice per group). The expression
levels of villin 1 (A), cytokeratin 8 (B), and cytokeratin 20 (C) in
colonic scrapings were analyzed by real-time PCR. Error bars =6
standard error of the mean.
(TIF)
Figure S4 NFkB and AP1 activity in the colons of
PPARcVillinCre+ mice after S. Typhimurium infection.
Electromobility shift assay of NFkB activity (A) and AP-1 activity
(B) in nuclear extracts from colonic scrapings of PPARcVillinCre+
(Cre+) or PPARcVillinCre2 (Cre2) mice 24 h after mock (Con)-
or S. Typhimurium (SaI)-infection (6 mice per group).
(TIF)
Figure S5 Determination of the efficiency of tissue-
specific PPARc ablation. Groups of 8–10-week-old, strepto-
mycin-pretreated C57BL/6 (WT), PPARcVillinCre+ (Cre+), or
littermate control PPARcVillinCre2 (Cre2) mice were mock
(Con)- or S. Typhimurium (SaI)-infected and sacrificed after 24 h
(6–8 mice per group). (A) PPARc expression in colonic scrapings
was analyzed by real-time PCR. Error bars =6 standard error of
the mean. *p,0.001 vs. WT or Cre- mice. NS, not significant. (B)
Electromobility shift assay of PPARc activity in nuclear extracts of
colonic scrapings.
(TIF)
Figure S6 Determination of the efficiency of the Lcn22/2
mousemodel. (A and B) Groups of 8–10-week old, streptomycin-
pretreated Lcn2+/+ and Lcn22/2 mice were mock (Con)- or S.
Typhimurium (SaI)-infected and sacrificed after 24 h (6–8 mice per
group). Lcn2 expression in the colon was analyzed by real-time
PCR (A) or by immunoblotting (B). Error bars =6 standard error of
the mean. *p,0.005 vs. Lcn2+/+ control.
(TIF)
Figure S7 Determination of basal secretion of gelatinases
and expression ofMMP-2 andTIMP-1 in Lcn22/2mice. (A)
Secretion of MMP-9 and MMP-2 in the colons of mock (Con)-
infected PPARcVillinCre2 or Lcn22/2 mice (6–8 mice per group)
was analyzed by gelatin zymography using gelatin-agarose-purified
PBS extracts. Expression levels of MMP-2 (B) and TIMP-1 (C) in the
colons of mock- or S. Typhimurium (SaI)-infected Lcn2+/+ and
Lcn22/2 mice were measured by real-time PCR (6–8 mice per
group). Error bars=6 standard error of the mean. NS, not
significant.
(TIF)
Figure S8 Assessment of mechanistic differences be-
tween Lcn2+/+ and Lcn22/2 mice during S. Typhimur-
ium infection. Expression levels of PPARc (A), TNF-a (B),
IL-6 (C), IL-17 (D), IL-22 (E), and Reg3c (F) in the colons of
mock (Con)- or S. Typhimurium (SaI)-infected Lcn2+/+ and
Lcn22/2 mice were measured by real-time PCR (6–8 mice per
group). Error bars =6 standard error of the mean. NS, not
significant.
(TIF)
Figure S9 Severity of colitis 72 h after S. Typhimurium
infection in mice. Groups of age-matched, streptomycin-
pretreated PPARcVillinCre+ (Cre+), littermate control PPARc-
VillinCre2 (Cre2), Lcn22/2, and littermate control Lcn2+/+
mice were mock (Con)- or S. Typhimurium (SaI)-infected and
sacrificed after 72 h (6 mice per group). (A) Macroscopic image of
whole cecum after mock or S. Typhimurium infection. (B)
Quantitation of colon lengths. Recovery of S. Typhimurium from
cecum tissue (C) and spleen (D) 72 h after infection. Sections of
colon from these mice were stained with hematoxylin and eosin
(E–T). PPARcVillinCre2 mice after mock infection (E and F), or
after S. Typhimurium infection (G and H). PPARcVillinCre+
mice after mock infection (I and J), or after infection with S.
Typhimurium (K and L). Lcn2+/+ mice after mock infection (M
and N), or after infection with S. Typhimurium (O and P). Lcn22/
2 mice after mock infection (Q and R), or after S. Typhimurium
infection (S and T). All scale bars are 500 mm. Pathology scoring
was carried out for neutrophil infiltration (U) and edema (V). (W)
Myeloperoxidase (MPO) activity in colonic extracts from mice,
measured per mg of total protein. PPARc expression in colonic
scrapings from PPARcVillinCre2 mice analyzed by real-time
PCR (X), and immunoblotting (Y). Error bars =6 standard error
of the mean. *p,0.005, **p,0.05 vs. appropriate control or as
indicated.
(TIF)
Table S1 Details of primers used for real-time RT-PCR
analysis of mouse colonic tissues and human cultured
cells. (A) The details of the mRNA of interest, sequence of primer
pairs with amplicon size used for RT-PCR analysis of mouse
colonic tissues. (B) The details of the mRNA of interest, sequence
of primer pairs with amplicon size used for RT-PCR analysis of
human cultured cells.
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